Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia

Blood

Volumn 122, Issue 2, 2013, Pages 170-178

  Pession, Andrea ^a   Masetti, Riccardo ^a   Rizzari, Carmelo ^b   Putti, Maria Caterina ^c   Casale, Fiorina ^d   Fagioli, Franca ^e   Luciani, Matteo ^f   Nigro, Luca Lo ^g   Menna, Giuseppe ^h   Micalizzi, Concetta ⁱ   Santoro, Nicola ^j   Testi, Anna Maria ^k   Zecca, Marco ^l   Biondi, Andrea ^b   Pigazzi, Martina ^c   Rutella, Sergio ^f   Rondelli, Roberto ^a   Basso, Giuseppe ^c   Locatelli, Franco ^f,m  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^f BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^g Azienda Policlinico   (Italy)

^h Ospedale Pausillipon   (Italy)

ⁱ G GASLINI INSTITUTE   (Italy)

^j POLICLINICO   (Italy)

^k SAPIENZA UNIVERSITY OF ROME   (Italy)

^l FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^m UNIVERSITY OF PAVIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CORE BINDING FACTOR; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; IDARUBICIN; MAFOSFAMIDE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW PURGING; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CHILD; CHILD DEATH; CHILDHOOD LEUKEMIA; CONSOLIDATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; GRAFT REJECTION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDUCTION CHEMOTHERAPY; INFANT; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALVAGE THERAPY; SCHOOL CHILD; TREATMENT FAILURE; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; CLINICAL TRIAL; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MORTALITY; NEWBORN; RECURRENT DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CONSOLIDATION CHEMOTHERAPY; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; RECURRENCE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84884488154     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-491621     Document Type: Article

References (49)

1. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011; 29(5):551-565.
2. Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica. 2007;92(11):1519-1532. (Pubitemid 350144128)
3. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al AML Committee of the International BFM Study Group. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16): 3187-3205.
4. Pession A, Rondelli R, Basso G, et al; AML Strategy & Study Committee of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP). Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia. 2005;19(12):2043-2053. (Pubitemid 41741596)
5. Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19(12): 2030-2042. (Pubitemid 41741595)
6. Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;19(12):2130-2138. (Pubitemid 41741605)
7. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6): 543-552.
8. Tsukimoto I, Tawa A, Horibe K, et al. Riskstratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27(24):4007-4013.
9. Hasle H, Abrahamsson J, Forestier E, et al Nordic Society of Paediatric Haematology and Oncology (NOPHO). Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood. 2012;120(5):978-984.
10. von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28(16):2682-2689.
11. Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010;28(16):2674-2681.
12. Amadori S, Testi AM, Aricò M, et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group. J Clin Oncol. 1993;11(6): 1046-1054. (Pubitemid 23163343)
13. Woods WG, Neudorf S, Gold S, et al Children's Cancer Group. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001;97(1):56-62. (Pubitemid 32061242)
14. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, Wheatley K; UK Medical Research Council Adult and Children's Leukaemia Working Parties. Randomised comparison of addition of autologous bonemarrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet. 1998; 351(9104):700-708. (Pubitemid 28105339)
15. Horan JT, Alonzo TA, Lyman GH, et al Children's Oncology Group. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol. 2008;26(35):5797-5801.
16. Niewerth D, Creutzig U, Bierings MB, Kaspers GJ. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood. 2010;116(13):2205-2214.
17. Klusmann JH, Reinhardt D, Zimmermann M, et al. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica. 2012;97(1):21-29.
18. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332(4):217-223.
19. Ravindranath Y, Yeager AM, Chang MN, et al Pediatric Oncology Group. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med. 1996; 334(22):1428-1434. (Pubitemid 26157438)
20. Locatelli F, Pession A, Bonetti F, et al. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes. Leukemia. 1994;8(5):844-849. (Pubitemid 24161092)
21. Bonetti F, Zecca M, Pession A, et al The Italian Association for Pediatric Hematology and Oncology-Bone Marrow Transplantation Group. Total-body irradiation and melphalan is a safe and effective conditioning regimen for autologous bone marrow transplantation in children with acute myeloid leukemia in first remission. J Clin Oncol. 1999;17(12):3729-3735.
22. Pession A, Dama E, Rondelli R, et al Italian Association of Paediatric Haematology and Oncology. Survival of children with cancer in Italy, 1989-98. A report from the hospital based registry of the Italian Association of Paediatric Haematology and Oncology (AIEOP). Eur J Cancer. 2008;44(9):1282-1289.
23. Gibson BE, Webb DK, Howman AJ, De Graaf SS, Harrison CJ, Wheatley K; United Kingdom Childhood Leukaemia Working Group and the Dutch Childhood Oncology Group. Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial. Br J Haematol. 2011;155(3):366-376.
24. Abrahamsson J, Forestier E, Heldrup J, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2011;29(3):310-315.
25. Rubnitz JE, Lensing S, Zhou Y, Sandlund JT, Razzouk BI, Ribeiro RC, Pui CH. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer. 2004;101(7):1677-1684. (Pubitemid 39318917)
26. Pichler H, Reismüller B, Steiner M, et al Austrian ALL-BFM (Berlin-Frankfurt-Münster) Study Group. The inferior prognosis of adolescents with acute lymphoblastic leukaemia (ALL) is caused by a higher rate of treatment-related mortality and not an increased relapse rate - a populationbased analysis of 25 years of the Austrian ALLBFM (Berlin-Frankfurt- Münster) Study Group. Br J Haematol. 2013;161(4):556-565.
27. Pui CH, Pei D, Campana D, et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol. 2011;29(4): 386-391.
28. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369-377.
29. Franklin J, Alonzo T, Hurwitz CA, et al. COG AAML03P1: Efficacy and safety in a pilot study of intensive chemotherapy including gemtuzumab in children newly diagnosed with acute myeloid leukemia (AML) [abstract]. Blood. 2008;112(11). Abstract 136.
30. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010;28(4):586-595.
31. Kaspers GJ, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013;31(5):599-607.
32. Creutzig U, Zimmermann M, Bourquin JP, et al. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood. 2011; 118(20):5409-5415.
33. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29): 4791-4797.
34. Hasle H, Alonzo TA, Auvrignon A, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood. 2007; 109(11):4641-4647. (Pubitemid 46827753)
35. Inaba H, Fan Y, Pounds S, et al. Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer. 2008; 113(3):522-529.
36. Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108(12):3654-3661. (Pubitemid 44864541)
37. Staffas A, Kanduri M, Hovland R, et al Nordic Society of Pediatric Hematology and Oncology (NOPHO). Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood. 2011;118(22):5905-5913.
38. Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia. 2003;17(9):1738-1752. (Pubitemid 37185249)
39. Meshinchi S, Arceci RJ, Sanders JE, Smith FO, Woods WB, Radich JP, Alonzo TA. Role of allogeneic stem cell transplantation in FLT3/ITDpositive AML. Blood. 2006;108(1):400, author reply 400-401. (Pubitemid 43990655)
40. DeZern AE, Sung A, Kim S, et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant. 2011;17(9):1404-1409.
41. Locatelli F, Zecca M, Messina C, et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia. 2002;16(11):2228-2237. (Pubitemid 35331838)
42. Dini G, Zecca M, Balduzzi A, et al; Associazione Italiana Ematologia ed Oncologia Pediatrica-Hematopoietic Stem Cell Transplantation (AIEOP-HSCT) Group. No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission. Blood. 2011; 118(25):6683-6690.
43. Bernardo ME, Piras E, Vacca A, et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood. 2012;120(2):473-476.
44. Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, Tsuchida M; Tokyo Children's Cancer Study Group. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group. Pediatr Blood Cancer. 2007;49(2):127-132. (Pubitemid 47041100)
45. Perel Y, Auvrignon A, Leblanc T, et al French LAME (Leucémie Aigu?e Myéloblastique Enfant) Cooperative Group. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit - multicenter studies of the French LAME (Leucémie Aigu?e Myéloblastique Enfant) Cooperative Group. Leukemia. 2005;19(12): 2082-2089. (Pubitemid 41741600)
46. Burnett AK, Goldstone A, Hills RK, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol. 2013;31(10):1293-1301.
47. Baker KS, Bhatia S, Bunin N, et al. NCI, NHLBI first international consensus conference on late effects after pediatric hematopoietic cell transplantation: state of the science, future directions. Biol Blood Marrow Transplant. 2011; 17(10):1424-1427.
48. Pigazzi M, Manara E, Bisio V, et al. Screening of novel genetic aberrations in pediatric acute myeloid leukemia: a report from the AIEOP AML-2002 study group. Blood. 2012;120(18): 3860-3862.
49. Masetti R, Pigazzi M, Togni M, et al. CBFA2T3- GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood. 2013; 121(17):3469-3472.